Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Terminated × Nivolumab × Clear all

Phase

Phase 2 90 Phase 1 56 Phase 1/2 50 Phase 3 9 Phase EARLY_PHASE1 4 Phase 2/3 2 Phase NA 1 Phase 4 1

Status

Completed 7 Recruiting 4 Unknown 2 Not yet recruiting 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thoracic Neoplasms 1 Lung Neoplasms 1 Lung Diseases 1

Interventions

Saline Solution 6 Fentanyl 6 Sodium Chloride 5 Letrozole 5 Pregabalin 4 Ketamine 4 Goserelin 4 Gemcitabine 4 Dexamethasone 4 Bevacizumab 4 Tranexamic Acid 3 Photochemotherapy 3 Pemetrexed 3 Paclitaxel 3 Metformin 3 Leuprolide 3 Docetaxel 3 Cyclophosphamide 3 Carboplatin 3 Capecitabine 3 Acetaminophen 3 ulipristal acetate 2 sodium glycididazole 2 nilotinib 2 liposomal doxorubicin 2 human papillomavirus vaccine, L1 type 16, 18 2 flurbiprofen axetil 2 fludarabine 2 fluciclovine F-18 2 epoetin beta 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05583188 2024-07-19

VIGOR

Galvanize Therapeutics, Inc.

Phase 4 Terminated

Lung Diseases, Lung Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡